Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK.
Kostenuik PJ, et al. Among authors: stolina m.
J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112.
J Bone Miner Res. 2009.
PMID: 19016581
Free article.